Emerging Health Care Innovation Brief: Two Potential Treatments for Early Alzheimer’s Disease (April 27-May 10, 2023)
Download this Innovation Brief
Highlights
Highlights provide a timely synopsis of selected interesting developments emerging in the past 2 weeks from the information universe covered by the PCORI Health Care Horizon Scanning System (HCHSS). Information covers currently emerging innovations in patient-centered care that may or may not be directly related to the Topics to Watch. The views presented here are solely those of ECRI Horizon Scanning and have not been vetted by other stakeholders.
The health care world reached several important milestones in the past 2 weeks.
First, the World Health Organization (WHO) stated that COVID-19 is now an established ongoing health issue and called an end to the COVID-19 PHEIC (public health emergency of international concern) on May 5. In the United States, May 11 brought the end of the federal COVID-19 PHE (public health emergency) declaration. COVID-19 fell from the third leading cause of death in 2021 to the fourth leading cause of death in the United States in 2022.
Second, the US Food and Drug Administration (FDA) made two milestone approvals in fields long followed by PCORI's Health Care Horizon Scanning System.
One, Seres Therapeutics’s Vowst (fecal microbiota spores, live-brpk; formerly SER-109), is the first fecal microbiota treatment in a pill. Vowst, now approved to prevent recurrence of the bacterial infection Clostridioides difficile, and the field of fecal microbiota treatment has had a slow and controversial emergence.
The other approval, for GlaxoSmithKline’s Arexvy (respiratory syncytial virus [RSV]vaccine, adjuvanted; formerly RSVPreF3 OA), is the first ever vaccine for RSV. Vaccines for RSV have also had a troubled emergence, but on an even longer timescale.
This Brief’s Topics to Watch focus on treating early Alzheimer’s disease, another area of health care that is experiencing milestone approvals after many years of failure.
Topics to Watch
ECRI Horizon Scanning has selected the topics below as those with potential for impact within the PCORI HCHSS’s focus areas in the United States within the next three years. All views presented are preliminary and based on readily available information at the time of writing. Because these topics are rapidly developing, we cannot guarantee the accuracy of this information after the date listed on this publication. In addition, all views expressed in the commentary section are solely those of ECRI Horizon Scanning and have not been vetted by other stakeholders. Topics are listed in alphabetical order.
Donanemab (LY3002813) to Treat Early Alzheimer's Disease
At a Glance
|
For a description and commentary about this topic/issue, download this Innovation Brief.
Valiltramiprosate (ALZ-801) to Treat Early Alzheimer's Disease
At a Glance
|
For a description and commentary about this topic/issue, download this Innovation Brief.
Horizon scanning is a systematic process that serves as an early alert system to inform decision makers about possible future opportunities and threats. Health care horizon scanning identifies technologies, innovations, and trends with the potential to cause future shifts or disruptions—positive or negative—in areas such as access to care, care delivery processes, care setting, costs of care, current treatment models or paradigms, health disparities, health care infrastructure, public health, and patient health outcomes.
The PCORI Health Care Horizon Scanning System (HCHSS) conducts horizon scanning to better inform research investments at the Patient-Centered Outcomes Research Institute (PCORI). PCORI defines the HCHSS project scope to focus on interventions with high potential for disruption in the United States in the next 12 months within 6 focus areas: Alzheimer’s disease and other dementias, cancer, cardiovascular diseases, infectious diseases (including COVID-19), mental and behavioral health conditions, and rare diseases. In addition, the system captures high-level disruptive trends across all clinical areas, which may lead PCORI to expand the project scope to include other focus areas in the future.
The HCHSS produces 3 main outputs:
- Emerging Health Care Innovation Brief provides ECRI Horizon Scanning with a vehicle to inform PCORI and the public in a timely manner of important topics of interest identified during ongoing scanning and topic identification or through the ECRI stakeholder survey process.
- PCORI’s Horizon Scanning Database offers health care decision makers findings about advancements in the HCHSS’s 6 focus areas. This database can be used by patients, care partners, and others to track advancements in care options.
- High Potential Disruption Reports (every 6 months) for individuals with vested interests in new technologies, services, and innovations. It might provide critical insights and information about the areas in which they have a vested interest, which might include their vision and plans for how they intend to adopt an innovation. These reports highlight those topics that stakeholders (eg, patients, physicians, nurses, allied health professionals, public health professionals, first responders, health systems experts, clinical engineers, researchers, business and finance professionals, and information technology professionals) identified as having potential for high disruption.
In January 2023, the HCHSS Biweekly COVID-19 Scans were broadened in scope to include any emerging intervention in the HCHSS and renamed as the Emerging Health Care Innovation Brief.
Back to Main Page Download this Innovation Brief
We welcome your comments on this Innovation Brief at [email protected].
Posted: May 19, 2023
What's Happening at PCORI?
The Patient-Centered Outcomes Research Institute sends weekly emails about opportunities to apply for funding, newly funded research studies and engagement projects, results of our funded research, webinars, and other new information posted on our site.
Image
